Intellia offering
Nettet30. jun. 2024 · Financing: In June 2024, Intellia closed an underwritten public offering of 6,301,370 shares of common stock, including the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $18.25 per share. Intellia received aggregate gross proceeds of approximately $115 million, before underwriting ... Nettet28. jun. 2024 · Intellia is developing NTLA-2001 with Regeneron Pharmaceutical under a collaboration that began in 2016. The deal calls for the partners to develop CRISPR-based therapies that target the liver...
Intellia offering
Did you know?
Nettet30. jun. 2024 · CAMBRIDGE, Mass., June 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … Nettet2. des. 2024 · CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Nettet12 timer siden · Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA-2.79%) and Rivian Automotive (RIVN-7.20% Nettet30. nov. 2024 · November 30, 2024 - 9:28 pm. CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an …
Nettet10. apr. 2024 · Sangharsh Lohakare. In a national first, the Food and Drug Administration has given Intellia Therapeutics the go-ahead to begin testing a drug that uses CRISPR gene editing in vivo.. In biology ... Nettet30. jun. 2024 · The offering is expected to close on or about July 2, 2024, subject to customary closing conditions. The shares of common stock are being offered by Intellia pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).
Nettet5. jul. 2024 · CAMBRIDGE, Mass. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the …
Nettet21. sep. 2024 · Intellia Therapeutics, Inc. (NASDAQ: ... (>$270 million) managed mainly from equity offerings, as seen with the most recent June 2024 $115 million public common stock offering. thin gaming laptop 14 inchNettet2. jul. 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the closing of an underwritten public offering of … thinga motors malelaneNettet28. jun. 2024 · Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the … thin gaming laptops 2021Nettet5. jan. 2024 · Intellia's stock bounced around throughout the year, eventually ending up 7%, which looks comparatively pretty meager. However, that does not mean investors … saints row the brotherhoodNettet4. des. 2024 · CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on … thin gaming laptops with cd playerNettetIntellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress - Yahoo Finance #YahooFinance… thin gaming laptop under 800Nettet2. jul. 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … saints row the third 2011